-
Jailed Pakistan ex-PM Khan moved to hospital on court order: party
-
Maradona trial on hold over possible medical evidence mix-up
-
Pogacar eyes 'missing' piece ahead of Vuelta return
-
'Green dilemma': China's solar boom hurt birds, says study
-
US, Canada 'very close' to trade deal, Ottawa says, as details emerge
-
Pegula hangs on to dispatch Anisimova, reach Cincinnati semi-finals
-
Ronaldinho returns in search of 'beautiful' 300th goal
-
US charges woman with IS-inspired plot to blow up New York State Capitol
-
US pushes allies, China to back Trump's economic war on Iran
-
What a record-breaking El Nino could mean for the world
-
Former NBA MVP Harden reportedly set to return to Cavaliers
-
Duplantis edges Karalis to win Lausanne Diamond League pole vault
-
Brook makes Pakistan pay for drop as England dominate first Test
-
Alcaraz to return for US Open title defence
-
MemeCore Arrives on Nasdaq Through $1 Billion Landmark Treasury Transaction
-
China's rapid solar expansion hurt bird diversity: study
-
First US deportees land in Liberia
-
President Paul Biya back in Cameroon after 73 days away
-
US, Canada resume talks to finalize trade deal as details emerge
-
Newcastle boss Jaissle unfazed by lack of respect
-
Europe heatwaves scorch 80 million with 40 C heat: AFP analysis
-
US Open purse to top $100 mn as Grand Slams form player council
-
Carrick insists Man Utd will make more signings after quiet transfer window
-
Hull aim to silence critics after unexpected promotion to Premier League
-
US warns allies, China to back economic war on Iran
-
Pakistan hit back against England after Cox and Root fifties
-
Manifesto defends Germany's iconic Bauhaus against 'populist attacks'
-
Walmart reports mixed results as gas prices drag on US sales growth
-
Kenya's Kipyegon ends season with hamstring injury
-
Wang downs Sindhu to break Indian hearts at badminton worlds
-
Nord Stream bomb suspect arrested while working on movie about attack: media
-
As Europe's rivers recede, shippers scramble to limit damage
-
German football fans plan widespread VAR protests
-
Alonso won't confirm Fernandez will remain at Chelsea after Man City link
-
Scorching summer triggers record rockfalls in Alps, scientist says
-
Milky Way's fastest star discovered spinning around black hole
-
Newly-crowned European champ Werro turns focus on 800m record
-
Kanye West planned concerts trigger frenzy in Russia
-
Hamilton 'fittest ever' as he chases eighth F1 title
-
Hungary music festival basks in post-Orban freedom
-
Stocks retreat as bond yield fears persist, oil rises
-
Vatican says 'serious concerns' over Israel-Lebanon deal implementation
-
ARKBRIDGE’s David Mali Highlights AI-Driven Risk Management at the Finance Magnates London Summit
-
Arteta confirms Arsenal want to sign defender after Konsa link
-
Zuckerberg buys Gothic castle in Ireland: spokesman
-
What's behind the UAE's decision to cut Iran trade ties?
-
Belgium's fire of the century now 'under control'
-
Barca seal Cancelo return to bolster defence
-
Evergrande's Xu Jiayin: from real-estate tycoon to life in prison
-
Germany reports record 14,000 heat-related deaths this summer
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection
Delivering Effective Germ Control in Five Minutes
BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.*
NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential.
"We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patient safety and manage infections more effectively."
The European Centre for Disease Prevention and Control reports that these infections result in over 3.5 million cases each year in the EU and EEA, causing more than 90,000 deaths. Effective infection control practices could prevent up to 50% of healthcare-associated infections (HAIs).* NUGEN® HLD-CD delivers powerful protection - arming frontline healthcare teams with a fast, effective tool to stop infections before they spread.
Additionally, NUGEN® HLD-CD is an ideal solution for targeting Clostridium difficile (C. diff) contamination*, a common and challenging pathogen in healthcare settings that spreads via contact with contaminated surfaces.
For more information about NUGEN® HLD-CD and its applications, please visit https://www.arxada.com/en/hygiene/hygiene-emea/nugen-hld-cd or contact [email protected]
Media contacts:
Tricia Ryan
External Corporate Communications
Arxada
[email protected]
Jane Smith
Marketing Communications, Professional Hygiene
Arxada
[email protected]
About Arxada
Arxada is a global science-based specialty chemicals business creating innovative chemistry and solutions. With customers in more than 100 countries, it achieved sales of CHF 2.0 billion in 2023. The company aims to solve the world's toughest preservation challenges by enhancing sustainability with cleaner, greener solutions. Arxada focuses on multiple end-markets, primarily in: Human Health & Nutrition, Home & Personal Care, Paints & Coatings and Wood Protection, providing a broad portfolio of differentiated products and solutions, supported by its and innovation capabilities, in-depth regulatory know-how and track record in manufacturing and process development. Headquartered in Basel (Switzerland), the company's 3,400 employees contribute to the success of its customers, spanning 24 production sites and 14 R&D centers. To learn more about Arxada, please visit: www.arxada.com and Arxada on LinkedIn.
This product is intended for use as a medical device within the European Union and is sold exclusively to healthcare professionals. It has undergone a conformity assessment to ensure compliance with EU regulations, including the Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. The product is designed to meet the highest standards of safety and performance. Users are advised to follow the instructions for use provided by the manufacturer. The manufacturer is not liable for any misuse or off-label use of the product. All trademarks belong to Arxada or its affiliates. © 2025 Arxada.
*Data on file with Arxada; based on internal and external testing
SOURCE: Enviro Tech Chemical Services, Inc.
View the original press release on ACCESS Newswire
X.AbuJaber--SF-PST